MedTrace Logo

Effects of Upper Extremity Aerobic Exercise Training in Patients With Interstitial Lung Disease

NCT05916404 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-07-21

No results posted yet for this study

Summary

Severe dyspnea, cough, fatigue, restrictive type ventilation disorder, decreased pulmonary function, impaired gas exchange, decreased cardiovascular function and exercise intolerance are frequently encountered findings in patients with interstitial lung disease. It was demonstrated exercise training has beneficial effects in patients with interstitial lung disease. However, no study investigated the effects of upper extremity aerobic exercise training on outcomes in patients with interstitial lung disease.

Conditions

Interventions

OTHER

Upper extremity high-intensity interval aerobic exercise training

High-intensity interval aerobic exercise training will be given to the training group on an arm ergometer 3 days in a week and 30-45 minutes a day for 6 weeks with the assistance of a physiotherapist. The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate. The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate. In case of desaturation (\<90%) during the training in the patients in the training group, O2 support with a nasal cannula will be given to the patient.

OTHER

Control Group

The control group will not be given any training during the 6-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.

Sponsors & Collaborators

  • Gazi University

    lead OTHER

Principal Investigators

  • Nazire Nur YILDIZ, M.Sc. · Gazi University

  • Meral BOŞNAK GÜÇLÜ, Prof. Dr. · Gazi University

  • Riad BEJTA, Pt. · Gazi University

  • Nilgün YILMAZ DEMİRCİ, Assoc. Prof. · Gazi University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-03
Primary Completion
2025-05-01
Completion
2025-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05916404 on ClinicalTrials.gov